Interleukin 6 News and Research

RSS

Interleukin-6 (IL-6) is a protein that in humans is encoded by the "IL6" gene. IL-6 is an interleukin that acts as both a pro-inflammatory and anti-inflammatory cytokine. It is secreted by T cells and macrophages to stimulate immune response to trauma, especially burns or other tissue damage leading to inflammation.

What links smoking, body fat, mental health, genes, and heart risk? Inflammation may be part of the answer

In a large UK Biobank study, higher levels of the chronic inflammation marker GlycA were associated with smaller heart chambers, thicker heart walls, impaired diastolic function, reduced stroke volume, and a 43% higher risk of major adverse cardiovascular events in the highest versus lowest GlycA group. Genetic susceptibility also modified the associations between environmental exposures, inflammation, and cardiovascular risk, while inflammatory proteins in the IL-1, TNF, and IL-6 pathways statistically mediated several of these associations.

23 Sep 2026

Regular exercisers show distinct metabolic and immune signatures in blood

Researchers compared blood samples from 40 regular exercisers and 46 sedentary adults and found differences in metabolites, blood chemistry, and immune cell gene activity. The patterns suggested greater fatty acid use and altered immune signaling among exercisers, but the study could not establish that exercise caused these differences.

21 Sep 2026

Shatavari may affect more than hormones, and the gut could help explain why

A review in Nutrients examined how bioactive compounds in Asparagus racemosus (Shatavari) may influence cognitive health through the microbiota-gut-brain axis, estrogen-related signaling, neuroinflammation, oxidative stress, and neurotransmitter regulation. Evidence from computational, cellular, animal, and limited human studies suggests several plausible biological pathways, but key questions remain about bioavailability, brain exposure, dosing, and clinical efficacy.

16 Sep 2026

Scientists tested how much whole grain makes a difference. The answer was not simply “more”

A meta-analysis of 87 randomized trials found that increasing whole-grain intake was associated with improvements in several cardiometabolic risk factors, although many individual changes were small or clinically unimportant. Dose-response analyses suggested that the magnitude of the effects varied by outcome and intake level, with limited evidence at very high intakes.

16 Sep 2026

Eating four to six wholegrain servings daily protects heart health

Eating four to six servings of wholegrain each day reduces several major risk factors for cardiovascular disease, according to a new study published in the European Heart Journal today (Wednesday).

16 Sep 2026

Cannabis-derived nanovesicles showed early antitumor potential in mice

Researchers developed a Cannabis sativa hairy root culture system that produced stable plant-derived nanovesicles capable of promoting dendritic cell maturation and activating T-cell responses through TLR2- and TLR4-associated signaling. Oral administration also restored selected immune responses in immunosuppressed mice and suppressed tumor growth in an E.G7 lymphoma model, providing preliminary evidence for their immunomodulatory and antitumor potential.

15 Sep 2026

Gut microbiome may reveal inflammation and future disease risk better than age

Gut microbiota composition explained more variation than chronological age in nearly all inflammatory cytokines and most physiological measures examined, with specific microbial profiles linked to markedly different patterns of inflammation across adulthood. People with the Bacteroides 2 enterotype showed an inflammaging-like profile decades earlier than other groups and had a higher risk of subsequent disease, while a high-diversity microbiota profile was associated with lower inflammation and reduced disease incidence.

9 Sep 2026

What your gut microbes may have to do with how your brain ages

This review examines how diet-driven changes in the gut microbiota and microbial metabolites may influence cognitive aging through immune, metabolic, neural, endocrine, and barrier-related pathways. It highlights SCFAs, tryptophan-derived metabolites, and bile acids as key signaling mediators while emphasizing that much of the mechanistic evidence remains preclinical and human evidence is largely associative.

3 Sep 2026

The four-day week has plenty of fans. Now researchers are testing what it really changes

The Sussex 4-Day Week study is a 14-week UK protocol designed to investigate how reduced working hours affect physical and mental health, wellbeing, sleep, work performance, and potential biological and psychological mechanisms. Researchers aim to combine questionnaires with actigraphy, inflammatory biomarkers, interoception testing, and brain imaging in at least 150 adults, with data collection expected to continue until 2027.

3 Sep 2026

Semaglutide did more than cut weight in this analysis of 6,239 adults

A systematic review and meta-analysis of nine randomized controlled trials involving 6,239 adults with overweight or obesity without diabetes found that subcutaneous semaglutide produced substantially greater reductions in body weight, waist circumference, and C-reactive protein than placebo. The higher dose of 7.2 mg semaglutide showed potential for greater weight loss, although the evidence is largely based on a single trial and requires confirmation.

31 Aug 2026

A personalized elimination diet changed the gut microbiome in people with migraine

In a 12-week randomized, sham-controlled trial of 98 adults with migraine, eliminating IgG-positive foods altered gut microbial composition and produced a greater reduction in serum zonulin than a sham elimination diet. The microbial changes were associated with previously reported reductions in CGRP and IL-6 and improvements in migraine and sleep, although the authors emphasized that these mechanistic links remain exploratory.

31 Aug 2026

Investigational anti-interleukin-6 monoclonal antibody achieves durable inflammatory biomarker reductions

The investigational anti-interleukin-6 (IL-6) monoclonal antibody pacibekitug produced sustained reductions in inflammation-related biomarkers through six months in patients with chronic kidney disease and elevated inflammatory risk associated with heart disease.

29 Aug 2026

Pacibekitug safely reduces inflammatory biomarkers in kidney disease patients

The interleukin-6 (IL-6) antibody, pacibekitug, produced sustained reductions in inflammatory biomarkers in patients with chronic kidney disease at high inflammatory risk, according to results from the phase II TRANQUILITY trial presented in a Hot Line session today at ESC Congress 2026.

29 Aug 2026

New stroke guidelines could help pave the way for precision rehabilitation

A University of Maryland School of Medicine (UMSOM) stroke rehabilitation specialist helped develop new recommendations for studying molecular biomarkers associated with recovery from stroke.

28 Aug 2026

Probiotics for mental health? A new review finds promising signals and major gaps

This narrative review examines how psychobiotics may influence anxiety, depression, bipolar disorder, and schizophrenia through gut-brain pathways involving neurotransmitters, inflammation, immune regulation, gut barrier function, and stress signaling. Specific Lactobacillus and Bifidobacterium strains showed encouraging effects, but wide differences in strains, doses, populations, and study designs currently limit clinical translation.

28 Aug 2026

The US switch in shingles vaccines revealed an unexpected heart health pattern

In a natural experiment involving 72,920 propensity-matched US adults aged 60 years and older, recombinant shingles vaccination was associated with a 9% lower cardiovascular disease burden over seven years compared with the live attenuated vaccine. Lower burdens of ischemic heart disease and heart failure were seen in both sexes, while ischemic stroke was significantly lower only among men, supporting further clinical trials and mechanistic studies

27 Aug 2026

New mutant rat model replicates human chronic kidney disease

Chronic kidney disease (CKD) is a major health burden affecting approximately one in ten adults globally. Even with improved treatments, many patients continue to have worsening loss of kidney function, resulting in the need for dialysis or transplantation.

27 Aug 2026

What decades of wine research can, and cannot, tell us about health

A narrative review found that moderate wine intake has repeatedly been associated with lower all-cause and cardiovascular mortality, with proposed mechanisms involving ethanol and grape-derived polyphenols, but the evidence remains largely observational and cannot establish causation. The authors argue that drinking pattern, beverage type, age, cancer risk, and risk-modeling choices all influence how the J-shaped association should be interpreted and how alcohol guidelines are developed.

25 Aug 2026

Glioma microenvironment emerges as key target for future therapies

The prognosis for glioma patients remains extremely poor despite aggressive multimodal standard therapy: maximal safe resection, radiotherapy, and temozolomide chemotherapy, with median survival rarely exceeding 15 to 18 months.

20 Aug 2026

Researchers put olive and fish oil IV nutrition under the microscope

A systematic review of six randomized trials compared olive-oil-based and fish-oil-containing parenteral nutrition in hospitalized adults, examining infection, inflammation, oxidative stress, liver function, and clinical outcomes. The included studies involved diverse patient groups and lipid formulations, with substantial variation in outcomes and insufficient evidence for a meta-analysis.

18 Aug 2026